

Freedom of Information Request: Our Reference CTMUHB_267_23

You asked:

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

There are 72 distinct patients recorded, receiving treatment for Multiple Myeloma and related disorders.

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- **Belantamab Mafodotin [Blenrep] - 0**
- **Bortezomib [Velcade] monotherapy or with dexamethasone - 5**
- **Bortezomib, thalidomide and dexamethasone [VTD] - 0**
- **Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) - 7**
- **Carfilzomib [Kyprolis] and dexamethasone - 0**
- **Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone - 0**
- **Daratumumab [Darzalex] monotherapy - Less than 5**
- **Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) - 18**
- **Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) - 7**
- **Elranatamab - 0**
- **Idecabtagene vicleucel [Abecma] - 0**
- **Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) - Less than 5**
- **Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) - 7**
- **Lenalidomide [Revlimid] monotherapy - 9**
- **Lenalidomide [Revlimid] and dexamethasone - 12**
- **Pomalidomide [Imnovid] and dexamethasone - 6**
- **Selinexor and dexamethasone - 0**
- **Talquetamab - 0**
- **Teclistamab [Tecvayli] - 0**
- **Any other systemic anti-cancer therapy - Less than 5**

Please note the following:

- Data Period 4/1/23-3/7/23 – patients for Cwm Taf Morgannwg University Health Board only.
- Data only includes information recorded in the South East Wales Haematology Network e-prescribing system. Other data sources may be available (e.g paper scripts still in use).
- Excluded data
 - all planned prescriptions that were never confirmed and authorised (and therefore never given).
 - Patients who only received the following
 - Zolendronic Acid
 - Cycloprime
 - Pentamidine
- Where the figures are less than 5, the exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test